l-161982

Description

L-161982: A prostanoid EP4 receptor antagonist [MeSH]

N-[2-[4-[[3-butyl-5-oxo-1-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]phenyl]phenyl]sulfonyl-3-methyl-2-thiophenecarboxamide : no description available [CHeBI]

Cross-References

ID Source	ID
PubMed CID	9961192
CHEMBL ID	97688
CHEMBL ID	1179743
SCHEMBL ID	238048
SCHEMBL ID	2365748
CHEBI ID	92695
MeSH ID	M0496058

Synonyms (33)

Synonym
CHEMBL97688 ,
bdbm50039902
4''-[3-butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1,5-dihydro-[1,2,4]triazol-4-ylmethyl]-biphenyl-2-sulfonic acid (3-methyl-thiophene-2-carbonyl)-amide; compound with dichloro-methane
HMS3269M17
BRD-K39733634-001-01-8
l-161982
NCGC00167757-01
CHEMBL1179743
l-161,982
l 161982
l161982
147776-06-5
SCHEMBL238048
SCHEMBL2365748
n-[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4h-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-3-methyl-2-thiophenecarboxamide
AKOS024457143
DTXSID50433324
CHEBI:92695
J-008411
n-[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4h-1,2,4-triazol-4-yl]methyl] [1,1'-biphenyl]-2-yl]sulfonyl]-3-methyl-2-thiophenecarboxamide
mmdnktxnuzfvkd-uhfffaoysa-n
NCGC00167757-04
NCGC00167757-03
Q27164396
n-[2-[4-[[3-butyl-5-oxo-1-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]phenyl]phenyl]sulfonyl-3-methyl-2-thiophenecarboxamide
HY-108559
HMS3677F03
HMS3413F03
BCP30004
l-161,982; l 161,982; l161,982;l 161982; l161982
n-[2-[4-[[3-butyl-5-oxo-1-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-4-yl]methyl]phenyl]phenyl]sulfonyl-3-methylthiophene-2-carboxamide
CS-0029162
2-thiophenecarboxamide, n-[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4h-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-3-methyl-

Drug Classes (1)

Class	Description
biphenyls	Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.

Protein Targets (4)

Potency Measurements

Protein	Taxonomy	Measurement	Average (mM)	Bioassay(s)
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	44.6684	AID504847
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	17.7828	AID2546
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	37.6858	AID588579
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	39.8107	AID504327

Bioassays (13)

Assay ID	Title	Year	Journal	Article
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152	Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4 ISSN: 2211-1247	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347153	Confirmatory screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161	Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164	384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163	384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158	ZIKV-mCherry secondary qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156	DAPI mCherry counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.

Research

Studies (25)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (24.00)	29.6817
2010's	17 (68.00)	24.3611
2020's	2 (8.00)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	25 (100.00%)	84.16%

Substance	Classes	Roles	Relationship Strength
bay h 4502	biphenyls; imidazoles		low
candesartan cilexetil	biphenyls		low
4-biphenylylacetic acid	biphenyls; monocarboxylic acid	non-steroidal anti-inflammatory drug	low
fenbufen	4-oxo monocarboxylic acid; biphenyls	non-steroidal anti-inflammatory drug	low
3,3'-dichlorobenzidine	biphenyls; monochlorobenzenes; organochlorine compound		low
3,3'-diaminobenzidine	biphenyls; substituted aniline	histological dye	low
diphenyl	aromatic fungicide; benzenes; biphenyls	antifungal agrochemical; antimicrobial food preservative	low
benzidine	biphenyls; substituted aniline	carcinogenic agent	low
4-nitrobiphenyl	biphenyls		low
dianisidine	biphenyls		low
2-tolidine	biphenyls		low
n,n'-diacetylbenzidine	biphenyls		low
2-amino-4-phenylphenol	biphenyls		low
4-acetylaminobiphenyl	biphenyls		low
4-biphenylylacetic acid ethyl ester	biphenyls		low
brequinar	biphenyls; monocarboxylic acid; monofluorobenzenes; quinolinemonocarboxylic acid	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral agent; EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor; immunosuppressive agent; pyrimidine synthesis inhibitor	low
tasosartan	biphenyls		low
telmisartan	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic	low
clobuzarit	biphenyls; organochlorine compound		low
magnolol	biphenyls		low
honokiol	biphenyls		low
bitertanol	aromatic ether; biphenyls; secondary alcohol; triazoles		low
isodiospyrin	biphenyls		low
difenpiramide	biphenyls; monocarboxylic acid amide; pyridines	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug	low
2-(4-phenylphenoxy)propanoic acid	biphenyls		low
4-hydroxy-2',4',6'-trichlorobiphenyl	biphenyls; trichlorobenzene		low
4-hydroxy-2',3',4'-5'-tetrachlorobiphenyl	biphenyls; tetrachlorobenzene		low
dityrosine	biphenyls; non-proteinogenic alpha-amino acid; tyrosine derivative	biomarker	low
4,4'-bis(methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl	biphenyls; dichlorobenzene; sulfone		low
nitroflurbiprofen	biphenyls; carboxylic ester; nitrate ester; organofluorine compound	cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; EC 1.14.13.39 (nitric oxide synthase) inhibitor; geroprotector; non-steroidal anti-inflammatory drug; vasodilator agent	low
olmesartan medoxomil	biphenyls		low
4'-hydroxyflurbiprofen	biphenyls		low
dehydrodieugenol	biphenyls		low
bifeprunox	biphenyls		low
2-chloro-n-(4-chlorobiphenyl-2-yl)nicotinamide	anilide fungicide; biphenyls; monochlorobenzenes; pyridinecarboxamide	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor; environmental contaminant; xenobiotic	low
aucuparin	biphenyls		low
2-[(3,4-dimethoxyphenyl)methyl]-5-[4-(4-methoxyphenyl)phenyl]-1,3,4-oxadiazole	biphenyls		low
2-(2,5-dimethoxyphenyl)-5-[4-(4-methoxyphenyl)phenyl]-1,3,4-oxadiazole	biphenyls		low
(2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide)	biphenyls		low
4-phenylbenzoic acid (propan-2-ylideneamino) ester	biphenyls		low
N-[[(6-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-4-phenylbenzamide	biphenyls		low
4-phenyl-N-(2-propyl-5-tetrazolyl)benzamide	biphenyls		low
2-[(1-methyl-5-tetrazolyl)thio]-N-(2-phenylphenyl)acetamide	biphenyls		low
3-phenyl-5-(2-phenylphenyl)-1,2,4-oxadiazole	biphenyls		low
N-[[methyl-(phenylmethyl)amino]-sulfanylidenemethyl]-4-phenylbenzamide	biphenyls		low
N-[4-[4-(ethylsulfonylamino)-3-methoxyphenyl]-2-methoxyphenyl]ethanesulfonamide	biphenyls		low
urb 597	biphenyls		low
3-(4-phenylphenyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine	biphenyls		low
ac 55649	biphenyls; carboxybiphenyl		low
1-[3-(4-phenylphenoxy)propyl]-1,2,4-triazole	biphenyls		low
N-[2-(2-phenylphenoxy)ethyl]-2-furancarboxamide	biphenyls		low
2-(2-phenylanilino)-N-(phenylmethyl)acetamide	biphenyls		low
4-(2-fluorophenyl)-N-(2-methylbut-3-yn-2-yl)benzamide	biphenyls		low
5-oxo-3-(4-phenylphenyl)-2H-furan-4-carbonitrile	biphenyls		low
N-([biphenyl]-2-yl)-3-cyclopentylpropanamide	biphenyls; cyclopentanes; secondary carboxamide		low
1-(4-morpholinyl)-2-(4-phenylphenoxy)-1-propanone	biphenyls		low
2-(4-morpholinyl)-N-(2-phenylphenyl)propanamide	biphenyls		low
4-[4-[2-hydroxy-3-(4-morpholinyl)propoxy]phenyl]benzonitrile	biphenyls; nitrile		low
3-[4-[(2-hydroxy-5-phenylphenyl)methyl]-1-piperazinyl]propanenitrile	biphenyls		low
N-(2-methoxyethyl)-4-[4-(2-methoxyethylsulfamoyl)phenyl]benzenesulfonamide	biphenyls		low
2-phenylbutanoic acid [2-oxo-2-(2-phenylanilino)ethyl] ester	biphenyls		low
2-(4-benzoyl-1-piperazinyl)-N-(2-phenylphenyl)propanamide	biphenyls		low
fexaramine	biphenyls		low
alx 5407	biphenyls		low
bay 12-9566	biphenyls; organochlorine compound		low
sacubitril	biphenyls		low
biphenyl-indanone a	biphenyls		low
fimasartan	biphenyls		low
2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid	biphenyls; organobromine compound		low
N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide	1,3,4-oxadiazoles; benzamides; biphenyls; nitrile	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
abt-737	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor	low
4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide	biphenyls		low
ly2183240	biphenyls		low
fluxapyroxad	anilide fungicide; aromatic amide; biphenyls; pyrazoles; trifluorobenzene	antifungal agrochemical; EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor	low
(3R,3aS,7R,7aS)-3-[4-[4-(dimethylamino)phenyl]-2-fluorophenyl]-7-methyl-2-(phenylmethyl)-3a,6,7,7a-tetrahydro-3H-isoindol-1-one	biphenyls		low
3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide	biphenyls		low
WWL113	biphenyls		low
lde225	aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound	antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist	low
N-[3-(3-chlorophenyl)phenyl]-1-(3-isoxazolylmethyl)-4-piperidinecarboxamide	biphenyls; organochlorine compound		low
N-[3-(3-chlorophenyl)phenyl]-1-(3-oxolanylmethyl)-4-piperidinecarboxamide	biphenyls; organochlorine compound		low
4-(4-acetyloxyphenyl)benzoic acid [2-[[2-(2-chloroanilino)-2-oxoethyl]-methylamino]-2-oxoethyl] ester	biphenyls		low
N-cyclopropyl-3-{4-[(cyclopropylmethyl)carbamoyl]phenyl}-4-methylbenzamide	benzamides; biphenyls; cyclopropanes; dicarboxylic acid diamide	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor	low
tak-875	biphenyls		low
bms-790052	biphenyls; carbamate ester; carboxamide; imidazoles; valine derivative	antiviral drug; nonstructural protein 5A inhibitor	low
(2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol	biphenyls		low
4-[(1-methyl-5-tetrazolyl)thio]-5-(4-phenylphenyl)thieno[2,3-d]pyrimidine	biphenyls; thienopyrimidine		low
ml228 probe	1,2,4-triazines; biphenyls; pyridines; secondary amino compound	hypoxia-inducible factor pathway activator	low
a 769662	biphenyls		low

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's
gamma-aminobutyric acid	1	amino acid zwitterion; gamma-amino acid; monocarboxylic acid	human metabolite; neurotransmitter; Saccharomyces cerevisiae metabolite; signalling molecule	2006	2006	18.0	low	1	0
dimethyl sulfoxide	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger	2006	2006	18.0	low	1	0
formaldehyde	1	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2006	2006	18.0	low	1	0
pyridoxal phosphate	1	methylpyridines; monohydroxypyridine; pyridinecarbaldehyde; vitamin B6 phosphate	coenzyme; cofactor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite	2015	2015	9.0	low	0	1
celecoxib	1	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug	2017	2017	7.0	low	0	1
indomethacin	1	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic	2007	2007	17.0	low	1	0
n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide	2	aromatic ether; C-nitro compound; sulfonamide	antineoplastic agent; cyclooxygenase 2 inhibitor	2013	2016	9.5	low	0	2
ondansetron	1	carbazoles		2015	2015	9.0	low	0	1
pd 98059	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector	2013	2013	11.0	low	0	1
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid	1	arenesulfonic acid; azobenzenes; methylpyridines; monohydroxypyridine; organic phosphate; pyridinecarbaldehyde	purinergic receptor P2X antagonist	2015	2015	9.0	low	0	1
puromycin aminonucleoside	1	3'-deoxyribonucleoside; adenosines		2006	2006	18.0	low	1	0
pyrroles	3	pyrrole; secondary amine		2007	2015	12.3	low	1	2
thiophenes	23	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent	2006	2017	11.4	high	6	17
acetylcysteine	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary	2015	2015	9.0	low	0	1
dideoxyadenosine	1	adenosines; purine 2',3'-dideoxyribonucleoside	EC 3.5.4.4 (adenosine deaminase) inhibitor; EC 4.6.1.1 (adenylate cyclase) inhibitor	2007	2007	17.0	low	1	0
phenyl acetate	1	benzenes; phenyl acetates		2006	2006	18.0	low	1	0
glutamic acid	1	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical	2006	2006	18.0	low	1	0
substance p	1	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent	2007	2007	17.0	low	1	0
2',5'-dideoxyadenosine	1	deoxyribonucleoside		2007	2007	17.0	low	1	0
triazoles	23	1,2,3-triazole		2006	2017	11.4	medium	6	17
ah 6809	6	xanthones		2006	2015	11.2	low	1	5
lubiprostone	1			2011	2011	13.0	low	0	1
arachidonic acid	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite	2013	2013	11.0	low	0	1
kt 5720	2	carboxylic ester; gamma-lactam; hemiaminal; indolocarbazole; organic heterooctacyclic compound; semisynthetic derivative; tertiary alcohol	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor	2007	2015	13.0	low	1	1
sc 560	1	aromatic ether; monochlorobenzenes; organofluorine compound; pyrazoles	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; cyclooxygenase 1 inhibitor; non-steroidal anti-inflammatory drug	2016	2016	8.0	low	0	1
dinoprostone	15	prostaglandins E	human metabolite; mouse metabolite; oxytocic	2007	2017	11.2	medium	4	11
alprostadil	4	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent	2007	2015	12.2	low	1	3
misoprostol	1			2006	2006	18.0	low	1	0
16,16-dimethylprostaglandin e2	1	cyclopentanones; monocarboxylic acid; prostanoid; secondary allylic alcohol	anti-ulcer drug; gastrointestinal drug; radiation protective agent	2012	2012	12.0	low	0	1
17-phenyltrinorprostaglandin e2	1	alicyclic ketone; beta-hydroxy ketone; hydroxy monocarboxylic acid; olefinic compound; oxo monocarboxylic acid; prostanoid; secondary alcohol	human metabolite; prostaglandin receptor agonist	2007	2007	17.0	low	1	0
ah 23848	1	(4Z)-7-{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid		2012	2012	12.0	low	0	1
taprostene	1	benzoic acids		2015	2015	9.0	low	0	1
sulprostone	1	prostanoid		2007	2007	17.0	low	1	0
semaxinib	1	olefinic compound; oxindoles; pyrroles	angiogenesis modulating agent; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist	2013	2013	11.0	low	0	1
l-826266	1			2006	2006	18.0	medium	1	0
mk-0524	1	indolyl carboxylic acid		2015	2015	9.0	low	0	1
butaprost	3			2007	2015	12.0	low	1	2
glucagon-like peptide 1	1			2013	2013	11.0	low	0	1
pf-04418948	1			2014	2014	10.0	low	0	1
cay 10580	1	hydroxy monocarboxylic acid; pyrrolidin-2-ones; secondary alcohol	prostaglandin receptor agonist	2015	2015	9.0	medium	0	1
interleukin-8	1			2015	2015	9.0	low	0	1
glucagon-like peptide 2	1			2013	2013	11.0	low	0	1
peptide yy	1			2013	2013	11.0	low	0	1

Condition	Studies	First Year	Last Year	Average Age	Relationship Strength	2000's	2010's
Adjuvant Arthritis	1	2017	2017	7.0	low	0	1
Allodynia	1	2006	2006	18.0	low	1	0
Angiogenesis, Pathologic	1	2015	2015	9.0	low	0	1
Anoxemia	1	2013	2013	11.0	low	0	1
Arthritis, Rheumatoid	1	2017	2017	7.0	low	0	1
Brain Ischemia	1	2016	2016	8.0	low	0	1
Cancer of Colon	1	2007	2007	17.0	low	1	0
Cancer of Mouth	1	2017	2017	7.0	low	0	1
Carcinoma, Epidermoid	1	2017	2017	7.0	low	0	1
Carcinoma, Squamous Cell	1	2017	2017	7.0	low	0	1
Cerebral Ischemia	1	2016	2016	8.0	low	0	1
Cholera Infantum	1	2015	2015	9.0	low	0	1
Choroid Neovascularization	1	2009	2009	15.0	low	1	0
Colonic Neoplasms	1	2007	2007	17.0	low	1	0
Congenital Zika Syndrome	1	2020	2020	4.0	low	0	1
Cystic Fibrosis	1	2011	2011	13.0	low	0	1
Cystic Fibrosis of Pancreas	1	2011	2011	13.0	low	0	1
Decerebrate Posturing	1	2015	2015	9.0	low	0	1
Disease Models, Animal	2	2009	2020	9.5	low	1	1
Hypoxia	1	2013	2013	11.0	low	0	1
Mouth Neoplasms	1	2017	2017	7.0	low	0	1
Muscle Contraction	1	2014	2014	10.0	low	0	1
Neovascularization, Optic Disc	1	2009	2009	15.0	low	1	0
Nephrosis	1	2006	2006	18.0	low	1	0
Neuroblastoma	1	2012	2012	12.0	low	0	1
Proteinuria	1	2006	2006	18.0	low	1	0
Retinal Neovascularization	1	2009	2009	15.0	low	1	0
Rheumatoid Arthritis	1	2017	2017	7.0	low	0	1
Schistosoma mansoni Infection	1	2015	2015	9.0	low	0	1
Schistosomiasis mansoni	1	2015	2015	9.0	low	0	1
Zika Virus Infection	1	2020	2020	4.0	low	0	1

Long-term Use (1)

Article	Year
The EP4 antagonist, L-161,982, induces apoptosis, cell cycle arrest, and inhibits prostaglandin E2-induced proliferation in oral squamous carcinoma Tca8113 cells. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, , Volume: 46, Issue:10	2017